Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
This study is currently recruiting participants.
Verified December 2012
by National Cancer Institute (NCI)
Study NCT01164228 Information provided by National Cancer Institute (NCI)
First Received on July 15, 2010. Last Updated on December 4, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Cancer
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Kidney Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
gemcitabine hydrochloride
sunitinib malate
Additional drug interventions recognized in this trial
Gemcitabine
Sunitinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
